SRX Global says CERo doses seventh patient in Phase 1/1b CER-1236 trial
SRXH•CERo reported dosing its seventh patient in the Phase 1/1b CERTAIN-T trial on November 3, 2026; preliminary results showed no dose-limiting toxicities among previously treated second-cohort patients, but do not establish CER-1236’s safety or efficacy.
1. Trial update
CERo, an acquisition target of SRX Global, reported dosing its seventh patient in the Phase 1/1b CERTAIN-T trial on November 3, 2026. Preliminary findings showed no dose-limiting toxicities among previously treated second-cohort patients, and infused therapeutic cells expanded after administration. The findings are insufficient to establish CER-1236’s safety or efficacy, and the acquisition remains pending.




